Michael Mack
Dr. Michael J. Mack is an internationally renowned cardiothoracic surgeon who has made significant contributions to research involving novel minimally invasive surgery and valvular heart disease therapies. Michael has been in practice since 1982 and has performed thousands of cardiac surgeries, of which well over 4,000 have involved heart valve procedures.
Dr. Mack has spent much of his career working closely with interventional cardiologists to improve the treatment of patients with cardiovascular disease. He played critical roles in the SYNTAX Trial, which compared percutaneous coronary intervention with coronary artery bypass graft surgery in patients with three-vessel or left main disease, and the PARTNER Trial, which explored the safety and efficacy of transcatheter aortic valve replacement. He has also authored or co-authored over 400 publications in peer-reviewed journals.
Dr. Mack is currently the Director of the Cardiovascular Service line at Baylor Scott & White Health System and Chairman of the Baylor Plano Research Center in Texas. Previously, he served as Medical Director Cardiovascular Disease and Transplantation at Medical City Dallas Hospital. Dr. Mack was President of the Society for Thoracic Surgeons (STS) in 2011 and a Past President of the Thoracic Surgery Foundation for Research and Education (TSFRE), the Southern Thoracic Surgical Association (STSA), and the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS). He is a member of the American College of Cardiology Foundation (ACCF) Board of Trustees and the ACC Interventional Scientific Council. He received his medical degree from St. Louis University in Missouri.
Latest contributions
Pioneers in TAVI
09 Sep 2024
Meet some of the first generation of pioneers that have inspired many thousands of interventionalists and learn more about the many obstacles they were obliged to along their journey.
Twenty years of progress - What we have achieved - LIVE case
27 Nov 2022 – From PCR London Valves 2022
- Part 1: TAVI by axillary access (Live)
An 80-year-old female with peripheral arterial disease presents a symptomatic severe aortic stenosis with small annulus and preserved LV function.
The operators implant, by axillary access, an Evolut pro 26 mm, on general anaesthesia, with predilatation (Balloon 18 mm) and post-dilatation...
EAPCI: patient initiatives around the world
22 Nov 2021 – From PCR London Valves 2021
In this session, you can find out more about the EAPCI Valve for Life initiative and what progress has been made in selected countries, as well as other collaborative initiatives across the world.
Aortic stenosis in the younger patient: procedural complications and lifetime management
21 Nov 2021 – From PCR London Valves 2021
Biological, surgical valves and TAVIs are being implanted in younger and younger patients. Since these procedures must be planned in the best possible way to minimize future complications, and because the lifetime management of these patients must be thought of, watch this session to get very useful...
Mitral valve disease: guidelines and beyond
21 Nov 2021 – From PCR London Valves 2021
In this session from PCR London Valves 2021 dedicated to the new guidelines relating to the management of mitral valve disease, discover how to apply them in your everyday clinical practice to the care of your patients through presentations, interviews, heart team discussions, a live case...
TAVI or SAVR for aortic stenosis: which modality for which patient?
22 Nov 2020 – From PCR Valves e-Course 2020
Watch this session if you want to hear the latest evidence guiding the choice between TAVI and SAVR in patients with severe aortic stenosis, to further appreciate the clinical and technical factors that determine the optimal mode of intervention and to integrate these insights into your...
Editorial - The “Interventional cardiac surgeon”: the (new) member of the interventional Heart Team
18 Nov 2020
Surgeons have been for many years the only interventionalists. The only “doctors” to dare enter the body and mechanically intervene on structures to cure or improve quality of life. The link between surgeons and interventional cardiologists is very strong. Many surgeons contributed to the development of...
Author
Author
Author
Low risk TAVI trials in the real world: where are we in 2020?
26 Jun 2020 – From PCR e-Course 2020
Watch this case discussion if you want to fully appreciate the impact of the low risk TAVI trials, to understand how to apply this information in your daily clinical practice and to translate clinical trial outcomes into real-world decisions by your Heart Team.
This session was originally...
Secondary mitral regurgitation in 2019: mastering the full spectrum of treatment options
19 Nov 2019 – From PCR London Valves 2019
Consult this session on secondary mitral regurgitation to update your knowledge regarding the contemporary evidence base for its management, and learn more about the complexity and variability of clinical presentation and the spectrum of therapeutic options, thanks to a selection of studies and clinical cases.
Spotlight - Challenges for the Heart Team I - A new interventional paradigm for aortic valve disease
18 Nov 2019 – From PCR London Valves 2019
Consult this session on aortic valve disease to learn more about the impact of the latest evidence concerning TAVI vs. SAVR on Heart Team discussions and patient choice (clinical and anatomical characteristics, redistribution of resources and training...), and discover how you and your colleagues can apply this information in...
